Takeda U.S. Unit Signs With Metabolex To Develop New Drugs
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceuticals' U.S. subsidiary has signed a contract with Metabolex to share research into new drugs. Metabolex of the United States specializes in treatments for diabetes and other metabolic diseases. Under the arrangement with Takeda San Francisco, the firms are to collaborate on developing a drug based on the Metabolex technology. Metabolix already has four drugs undergoing clinical trials, the most advanced of them just completed Phase II tests. (Click here for more
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.